Primary Objectives:~To identify dose-limiting toxicities (DLTs) and recommended phase 2 dose (RP2D) of the combination of paclitaxel/bevacizumab/lurbinectedin in women with platinum resistant ovarian cancer.~To assess macrophage counts by image cytometry in women with platinum resistant ovarian cancer treated with weekly paclitaxel/bevacizumab/lurbinectedin.~Secondary Objectives:~To assess objective response (OR) and duration of response (DOR).~To assess clinical benefit rate (CBR), defined as proportion of patients with OR or stable disease (SD) > 4 months.~To estimate progression free survival (PFS) and overall survival (OS) for at least 12 months~Exploratory Objectives:~--To assess differential effects from baseline, within and between patient treatment cohorts, on macrophage and hypoxia markers, CSF1/R and MHCII, plasma biomarker (VEGF, VEGFR, IL6, IL8, FGF, PDGFAA), tumor and macrophage-derived exosomes, resident macrophage populations in tissue pre-enrollment and after induction bevacizumab (CD11b +CD68, CD11b +CD14/CD15/CD33, CD11b +CD11c, MHCII, CD168+, CD4/CD8, NK, Treg) by multicolor tissue cytometry, as well as serial changes in vivo imaging such as tumor size, macrophage-specific imaging, ADC for cellularity, and DCE for vasculature.
To learn if adding lurbinectedin to the combination of paclitaxel and bevacizumab can help to control advanced cancer.